Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-951d8a8dc27e4bf24952f3a016066e45"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-951d8a8dc27e4bf24952f3a016066e45"/>
<resource>
<Composition>
<id value="composition-en-951d8a8dc27e4bf24952f3a016066e45"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-951d8a8dc27e4bf24952f3a016066e45"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-951d8a8dc27e4bf24952f3a016066e45</b></p><a name="composition-en-951d8a8dc27e4bf24952f3a016066e45"> </a><a name="hccomposition-en-951d8a8dc27e4bf24952f3a016066e45"> </a><a name="composition-en-951d8a8dc27e4bf24952f3a016066e45-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1782/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - omjjara</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/23/1782/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp951d8a8dc27e4bf24952f3a016066e45"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - omjjara"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Omjjara is and what it is used for</li><li>What you need to know before you take Omjjara</li><li>How to take Omjjara</li><li>Possible side effects</li><li>How to store Omjjara</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What omjjara is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What omjjara is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Omjjara contains the active substance momelotinib. Momelotinib is a type of medicine known as a protein kinase inhibitor.</p><p>Omjjara is used to treat enlarged spleen or other disease related symptoms in adult patients with myelofibrosis, a rare form of blood cancer, and moderate to severe anaemia.</p><p>In myelofibrosis, bone marrow is replaced by scar tissue and is classified as either: primary myelofibrosis, which develops in people who have not had problems with their bone marrow before, or; secondary myelofibrosis, which develops in people who have other blood cancers, causing their body to produce too many red blood cells (post polycythaemia vera myelofibrosis) or blood platelets, which help the blood to clot (post essential thrombocythemia myelofibrosis).</p><p>How Omjjara works</p><p>An enlarged spleen is one of the characteristics of myelofibrosis. Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue. The abnormal marrow can no longer produce enough normal blood cells and as a result the spleen becomes significantly enlarged. Omjjara blocks the action of certain proteins, called Janus Kinases (JAK1, JAK2) and activin A receptor, type 1 (ACVR1) preventing the over production of cytokines and reducing inflammation. By doing so, Omjjara relieves the enlarged spleen, anaemia, and symptoms such as fever, night sweats, bone pain and weight loss caused by myelofibrosis.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take omjjara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take omjjara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Omjjara</p><ul><li>if you are allergic to momelotinib or any of the other ingredients of this medicine (listed in section 6). If you are not sure whether this applies to you, do not take Omjjara until you have checked with your doctor.</li><li>if you are pregnant or breast-feeding.</li></ul><p>Warnings and precautions<br/>Tell your doctor<br/>Talk to your doctor, pharmacist, or nurse before taking Omjjara or during your treatment with Omjjara:</p><ul><li>if you have an infection or have frequent infections signs of an infection may include fever, chills, cough, breathing problems, diarrhoea, vomiting, pain or burning feeling when passing urine.</li><li>if you have had hepatitis B for a long time (chronic) as hepatitis B may become active again.</li><li>if you have unusual bleeding or bruising under the skin, longer than usual bleeding after your blood has been drawn, or bleeding from your gums these may be signs of low levels of blood platelets (components that help the blood to clot), also called thrombocytopenia.</li><li>if you have any liver problems. Your doctor may need to prescribe a lower dose of Omjjara.</li></ul><p>The following has been observed in another similar type of medicine used for the treatment of rheumatoid arthritis: heart problems, blood clots and cancer. Talk to your doctor or pharmacist before or during treatment:</p><ul><li>if you are older than 65. Patients aged 65 years and older may be at increased risk of heart problems including heart attack and some types of cancer.</li><li>if you have or have had heart problems.</li><li>if you have or have had cancer.</li><li>if you are a smoker or have smoked in the past.</li><li>if you have previously had blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) or if you have an increased risk of developing this, for example if:</li><li>you had recent major surgery.</li><li>you use hormonal contraceptives/hormonal replacement therapy.</li><li>you or a close relative have been diagnosed with a blood clotting disorder. Tell your doctor immediately if you get:</li><li>sudden shortness of breath or difficulty breathing.</li><li>chest pain or pain in upper back.</li><li>swelling of the leg or arm.</li><li>leg pain or tenderness.</li><li>redness or discolouration in the leg or arm. These can be signs of blood clots in the veins.</li><li>if you notice any new growths on the skin or changes in existing growths. Your doctor may recommend that you have regular skin examinations while taking Omjjara.</li></ul><p>Your doctor will discuss with you if Omjjara is appropriate for you.</p><p>Blood tests Before and during treatment, your doctor will carry out blood tests to check your blood cell levels (red blood cells, white blood cells and platelets) and your liver function. Your doctor may adjust the dose or stop treatment based on the results of the blood tests.</p><p>Children and adolescents Omjjara should not be given to children under 18 years of age, because this medicine has not been studied in this age group. Other medicines and Omjjara<br/>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken or might take any other medicines. This includes herbal preparations and medicines without a prescription. This is because Omjjara can affect the way some other medicines work. Also, some other medicines can affect the way Omjjara works.</p><p>It is particularly important that you mention any medicines containing any of the following active substances, as your doctor may need to adjust the dose of Omjjara or the other medicine.</p><p>The following may increase the risk of side effects with Omjjara:</p><ul><li>ciclosporin (used to prevent transplant rejection)</li></ul><p>The following may reduce the effectiveness of Omjjara:</p><ul><li>carbamazepine (used to treat epilepsy and control fits or convulsions)</li><li>phenobarbital (used to treat epilepsy and control fits or convulsions)</li><li>phenytoin (used to treat epilepsy and control fits or convulsions)</li><li>St John s wort (Hypericum perforatum), a herbal product</li></ul><p>Omjjara may affect other medicines:</p><ul><li>rosuvastatin (a statin used to lower cholesterol)</li><li>sulfasalazine (used to treat rheumatoid arthritis)</li><li>metformin (used to lower blood sugar levels)</li><li>theophylline (used to treat breathing problems)</li><li>tizanadine (used to treat muscle spasms)</li><li>cyclophosphamide (used to treat cancer)</li></ul><p>Pregnancy, breast-feeding and fertility Omjjara must not be used during pregnancy. If you are pregnant, think you may be pregnant or are planning to have a baby, do not take this medicine, as it could harm your baby. Talk to your doctor for advice.</p><p>If you are a woman who could become pregnant, you must use highly effective contraception while you are taking Omjjara and you must continue to use highly effective contraception for at least 1 week after taking your last dose. It is currently unknown if Omjjara could reduce the effectiveness of oral contraceptives, therefore it is recommended to add a barrier method during treatment and for at least 1 week after taking your last dose of Omjjara. Your doctor may ask you to take a pregnancy test before starting your treatment, to confirm that you are not pregnant. If you become pregnant while you are taking Omjjara, contact your doctor immediately.</p><p>Omjjara must not be used during breast-feeding. It is not known if it passes into breast milk. A risk to the breast-fed child cannot be excluded. Tell your doctor if you are breast-feeding before taking this medicine.</p><p>It is unknown if Omjjara affects male or female fertility in humans. Omjjara had effects on fertility in animals. If you or your partner are planning to have a baby, ask your doctor for advice before, or while taking, this medicine.</p><p>Driving and using machines<br/>Omjjara may have side effects that affect your ability to drive. If you feel dizzy or have blurred vision, do not drive or operate machines until these side effects have gone away.</p><p>Omjjara contains lactose and sodium Omjjara contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take omjjara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take omjjara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How much to take The recommended starting dose of Omjjara is 200 mg taken by mouth once daily.</p><p>Your doctor may recommend a lower dose if you have problems with your liver. If you get certain side effects (such as abnormal bleeding or bruising, diarrhoea or nausea) while you are taking Omjjara your doctor may recommend a lower dose, or pause or stop your treatment (see section 4).</p><p>How to take it Take Omjjara every day at the same time, with or without meals.</p><p>How long to take it Continue taking Omjjara for as long as your doctor tells you to. This is a long-term treatment.</p><p>Your doctor will regularly monitor your condition to make sure that the treatment is having the desired effect.</p><p>If you have questions about how long to take Omjjara, talk to your doctor.</p><p>If you take more Omjjara than you should<br/>If you accidentally take more Omjjara than your doctor prescribed, contact your doctor immediately.</p><p>If you forget to take Omjjara Simply take your next dose at the scheduled time the next day. Do not take a double dose to make up for a forgotten tablet.</p><p>If you stop taking Omjjara<br/>Do not stop taking Omjjara unless you have agreed this with your doctor. If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Talk to your doctor, pharmacist or nurse if you get any side effects that concern you.</p><p>Serious side effects</p><p>Some side effects could be serious. Seek medical help immediately before taking the next scheduled dose if you experience the following serious side effects:</p><p>Very common side effects</p><p>May affect more than 1 in 10 people:</p><ul><li>infections signs or symptoms may include fever, chills, cough, breathing problems, diarrhoea, vomiting, pain or burning feeling when passing urine</li><li>low blood platelet count (thrombocytopenia) which can result in bruising or bleeding for longer than usual if you hurt yourself</li></ul><p>Other side effects</p><p>Other possible side effects include the following listed below:</p><p>Very common side effects</p><p>May affect more than 1 in 10 people:</p><ul><li>dizziness</li><li>headache</li><li>cough</li><li>diarrhoea</li><li>feeling sick (nausea)</li><li>stomach ache (abdominal pain)</li><li>feeling weak (asthenia)</li><li>tiredness (fatigue)</li></ul><p>Common side effects</p><p>May affect up to 1 in 10 people:</p><ul><li>low level of a type of white blood cells (neutropenia) which can increase your risk of infection</li><li>vitamin B1 (thiamine) deficiency which can cause loss of appetite, lack of energy, irritability</li><li>numbness, tingling or weakness of the arms, hands, legs or feet (peripheral neuropathy)</li><li>abnormal tingling sensation (paraesthesia)</li><li>fainting (syncope)</li><li>spinning sensation (vertigo)</li><li>blurred vision</li><li>sudden reddening of the face, neck or upper chest (flushing)</li><li>localised bleeding under the skin (haematoma)</li><li>low blood pressure which can cause light-headedness when you stand up (hypotension)</li><li>constipation</li><li>vomiting</li><li>joint pain (arthralgia)</li><li>pain in limbs, hands or feet</li><li>fever (pyrexia)</li><li>changes in blood test results (alanine aminotransferase increased and aspartate aminotransferase increased). These may be signs of liver problems.</li><li>bruising (contusion)</li></ul><p>Tell your doctor, pharmacist or nurse if any of the side effects listed becomes severe or troublesome, or if you notice any side effects not listed in this leaflet.</p><p>Reporting of side effects<br/>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store omjjara"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store omjjara"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle label and carton after EXP . The expiry date refers to the last day of that month.</p><p>Store in the original bottle in order to protect from moisture. Do not remove the desiccant. Do not swallow the desiccant. This medicine does not require any special temperature storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Omjjara contains</p><p>The active substance is momelotinib.</p><ul><li>Each 100 mg film-coated tablet contains momelotinib dihydrochloride monohydrate equivalent to 100 mg of momelotinib.</li><li>Each 150 mg film-coated tablet contains momelotinib dihydrochloride monohydrate equivalent to 150 mg of momelotinib.</li><li>Each 200 mg film-coated tablet contains momelotinib dihydrochloride monohydrate equivalent to 200 mg of momelotinib.</li><li>The other excipients are: Tablet core: microcrystalline cellulose, lactose monohydrate, sodium starch glycolate (type A), magnesium stearate, silica colloidal anhydrous, and propyl gallate. Tablet coating: Opadry II brown containing polyvinyl alcohol, macrogols, titanium dioxide (E171), talc, iron oxide yellow (E172) and iron oxide red (E172).</li></ul><p>See section 2 Omjjara contains lactose and sodium.</p><p>What Omjjara looks like and contents of the pack</p><p>Omjjara 100 mg film-coated tablets are round-shaped brown tablets with an underlined M debossed on one side and 100 on the other side.</p><p>Omjjara 150 mg film-coated tablets are triangle-shaped brown tablets with an underlined M debossed on one side and 150 on the other side.</p><p>Omjjara 200 mg film-coated tablets are capsule shaped brown tablets with an underlined M debossed on one side and 200 on the other side.</p><p>Omjjara film-coated tablets are supplied in a white bottle with a seal and a child-resistant cap. Each bottle contains 30 tablets, a silica gel desiccant, a polyester coil, and is packed in a cardboard carton.</p><p>Marketing Authorisation Holder and Manufacturer<br/>GlaxoSmithKline Trading Services Limited 12 Riverwalk Citywest Business Campus Dublin Ireland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien GlaxoSmithKline Pharmaceuticals s.a./n.v. T l/Tel: + 32 (0)10 85 52 Lietuva GlaxoSmithKline (Ireland) Limited Tel: + 370 80000<br/>GlaxoSmithKline (Ireland) Limited Te .: + 359 80018Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v. Belgique/Belgien T l/Tel: + 32 (0)10 85 52 esk republika GlaxoSmithKline, s.r.o. Tel: + 420 222 001 <a href="mailto:cz.info@gsk.com">cz.info@gsk.com</a></p><p>Magyarorsz g GlaxoSmithKline (Ireland) Limited Tel.: + 36 80088Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 <a href="mailto:dk-info@gsk.com">dk-info@gsk.com</a></p><p>Malta GlaxoSmithKline Trading Services Limited<br/>Tel: + 356 80065Deutschland GlaxoSmithKline GmbH & Co. KG Tel.: + 49 (0)89 36044 <a href="mailto:8produkt.info@gsk.com">8produkt.info@gsk.com</a></p><p>Nederland GlaxoSmithKline BV Tel: + 31 (0)33 2081Eesti GlaxoSmithKline (Ireland) Limited Tel: + 372 <a href="mailto:8002ee@berlin-chemie.com">8002ee@berlin-chemie.com</a></p><p>Norge GlaxoSmithKline AS Tlf: + 47 22 70 20<br/>GlaxoSmithKline A.E.B.E. : + 30 210 68 82 sterreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 <a href="mailto:at.info@gsk.com">at.info@gsk.com</a></p><p>Espa a GlaxoSmithKline, S.A. Tel: + 34 900 202 <a href="mailto:es-ci@gsk.com">es-ci@gsk.com</a></p><p>Polska GSK Services Sp. Z o.o. Tel.: + 48 (0)22 576 9France Laboratoire GlaxoSmithKline T l: + 33 (0)1 39 17 84 <a href="mailto:diam@gsk.com">diam@gsk.com</a> Portugal GlaxoSmithKline Produtos Farmac uticos, Lda. Tel: + 351 21 412 95 <a href="mailto:FI.PT@gsk.com">FI.PT@gsk.com</a></p><p>Hrvatska GlaxoSmithKline (Ireland) Limited Tel: + 385 800787Rom nia GlaxoSmithKline Trading Services Limited<br/>Tel: + 40 800672Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955Slovenija GlaxoSmithKline (Ireland) Limited Tel: + 386 80688 sland Vistor hf. S mi: +354 535 7Slovensk republika GlaxoSmithKline (Ireland) Limited Tel: + 421 800500Italia GlaxoSmithKline S.p.A. Tel: + 39 (0)45 7741 Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30<br/>GlaxoSmithKline Trading Services Limited<br/>T : + 357 80070Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 <a href="mailto:info.produkt@gsk.com">info.produkt@gsk.com</a> Latvija GlaxoSmithKline (Ireland) Limited Tel: + 371 80205United Kingdom (Northern Ireland) GlaxoSmithKline Trading Services Limited<br/>+44(0)800 <a href="mailto:221customercontactuk@gsk.com">221customercontactuk@gsk.com</a></p><p>This leaflet was last revised in MM/YYYY</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp951d8a8dc27e4bf24952f3a016066e45"/>
<resource>
<MedicinalProductDefinition>
<id value="mp951d8a8dc27e4bf24952f3a016066e45"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp951d8a8dc27e4bf24952f3a016066e45"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp951d8a8dc27e4bf24952f3a016066e45</b></p><a name="mp951d8a8dc27e4bf24952f3a016066e45"> </a><a name="hcmp951d8a8dc27e4bf24952f3a016066e45"> </a><a name="mp951d8a8dc27e4bf24952f3a016066e45-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1782/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Omjjara 100 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/23/1782/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Omjjara 100 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
